立方制药三款产品拟中选集采，股价表现略强于医药板块

Core Viewpoint - Recent developments for Lifan Pharmaceutical (stock code: 003020) focus on product procurement progress and market performance, with three core products expected to enhance sales and market share through national procurement [1] Group 1: Recent Events - Product Procurement Selection: On February 10, 2026, Lifan Pharmaceutical announced that its three products—Nifedipine Controlled-Release Tablets, Venlafaxine Hydrochloride Sustained-Release Tablets, and Trimethoprim Sustained-Release Tablets—are proposed for selection in the national procurement program, which could significantly boost sales and market share [2] - New Drug Application Progress: On the same day, the application for the raw material drug Finerenone was accepted by the National Medical Products Administration, aimed at treating chronic kidney disease related to type 2 diabetes, currently under review [2] Group 2: Stock Performance - Stock Price Movement: Over the past week (February 5 to 11), the stock price fluctuated by 0.84%, with a high of 26.99 yuan on February 6 and a low of 26.22 yuan on February 9. The closing price on February 11 was 26.53 yuan, with a single-day increase of 0.53% and a trading volume of 30.08 million yuan [3] - Capital Flow Situation: On February 11, there was a net outflow of 1.7835 million yuan from institutional investors, while retail investors showed a net inflow, indicating overall stable liquidity [3] Group 3: Sector Performance - Sector Comparison: During the same period, the pharmaceutical and biotechnology sector declined by 0.50%, while Lifan Pharmaceutical's stock performance was slightly better than the sector average [4] Group 4: Institutional Insights - Strategic Transformation Analysis: On February 6, 2026, Morningstar Research noted that Lifan Pharmaceutical is focusing on high-barrier areas such as osmotic pump controlled-release technology and narcotic drugs, with core products like Methylphenidate Hydrochloride Sustained-Release Tablets already on the market. However, short-term performance may experience fluctuations, necessitating attention to new drug volume and balancing R&D investments [5]